Compare KGC & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KGC | DXCM |
|---|---|---|
| Founded | 1993 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4B | 31.7B |
| IPO Year | N/A | 2005 |
| Metric | KGC | DXCM |
|---|---|---|
| Price | $27.38 | $65.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 21 |
| Target Price | $28.80 | ★ $87.81 |
| AVG Volume (30 Days) | ★ 8.7M | 6.1M |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | ★ 137.72 | 7.75 |
| EPS | 1.43 | ★ 1.80 |
| Revenue | ★ $6,443,900,000.00 | $4,515,900,000.00 |
| Revenue This Year | $38.87 | $17.41 |
| Revenue Next Year | $16.85 | $12.78 |
| P/E Ratio | ★ $19.13 | $36.33 |
| Revenue Growth | ★ 32.90 | 14.21 |
| 52 Week Low | $9.00 | $54.11 |
| 52 Week High | $28.81 | $93.25 |
| Indicator | KGC | DXCM |
|---|---|---|
| Relative Strength Index (RSI) | 59.95 | 59.32 |
| Support Level | $26.88 | $61.08 |
| Resistance Level | $28.81 | $65.32 |
| Average True Range (ATR) | 1.09 | 1.85 |
| MACD | 0.18 | 0.95 |
| Stochastic Oscillator | 71.26 | 98.65 |
Kinross Gold is a Canada-based gold producer, producing roughly 2.1 million gold equivalent ounces in 2024. The company had about a decade of gold reserves at the end of 2024. It operates mines in the Americas and West Africa after selling its low-cost Russian operations in 2022 in response to the invasion of Ukraine. The company has historically used acquisitions to fuel expansion into new regions and production growth. In 2022, Kinross purchased the Great Bear project in Canada. If developed as we think likely, it could produce an average of more than 500,000 ounces of gold per year for at least a decade, with its unit cash costs likely in the first quartile of the industry cost curve.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.